Marketing
-
Coronavirus weighs on AstraZeneca's China expansion
The British drugmaker cautioned the disease outbreak could impact its sales in the country, where restrictions on travel and commerce have been imposed to contain the virus' spread.
By Jonathan Gardner • Feb. 14, 2020 -
Gilead launches ad campaign for key HIV drug
The drugmaker is working to expand PrEP use of Descovy as its older option Truvada loses patent protection later this year.
By Kristen Jensen • Feb. 12, 2020 -
Are Novartis and Regeneron seeing the same thing?
Both companies are touting the success of their competing eye drugs. But as the market crowds, it's likely they'll bump into problems.
By Jacob Bell • Feb. 07, 2020 -
AbbVie's plan to replace Humira is ahead of schedule
Sales of Skyrizi and Rinvoq, AbbVie's two new immunology drugs, jumped higher in the fourth quarter, leading the pharma to raise its 2020 forecasts for them by more than two-thirds.
By Ned Pagliarulo • Feb. 07, 2020 -
Biogen boosted as Mylan patent challenge fails
A patent court determined all 20 claims in a key Tecfidera patent are patentable, providing some near-term relief to Biogen and its top-seller.
By Jacob Bell • Feb. 05, 2020 -
FDA approves Aimmune drug as first treatment for peanut allergy
Aimmune's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.
By Jonathan Gardner • Jan. 31, 2020 -
Amgen, Pfizer biosimilar sales pressure top drugs
Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.
By Jonathan Gardner • Jan. 31, 2020 -
Novartis gives up on Advair generic, leaving Mylan as sole competitor
Development delays and an uncertain path forward led Novartis to discontinue further work on its knockoff version of the GlaxoSmithKline lung drug.
By Ned Pagliarulo • Jan. 29, 2020 -
Pfizer hits its biosimilar stride
The big pharma, which has criticized other companies for stifling the U.S. biosimilars market, is now poised to launch three of these copycat biologics in as many months.
By Jacob Bell • Jan. 27, 2020 -
SponsoredGoogle's call for change and what it means for advertisers
Last week, Google Chrome announced a vision for a future without third-party cookies. How will upcoming changes impact health marketers?
-
SponsoredAlternate sites of care: The changing face of healthcare delivery
As the care setting evolves and diversifies, stakeholders throughout the healthcare ecosystem have to evolve in kind.
By Parijat Sharma & Matt Ruple • Jan. 21, 2020 -
Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?
Amarin CEO John Thero had one question for investors eager to hear about his company's plans for its heart pill, while Orchard made a case for independence.
By Jacob Bell • Jan. 16, 2020 -
Lilly expands half-price insulin offerings
Like rivals Novo and Sanofi, Lilly has introduced lower cost insulin alternatives to head off criticism of list price increases it's taken on its branded versions.
By Ned Pagliarulo • Jan. 15, 2020 -
Nektar quickly drops opioid drug after FDA panel rejection
After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.
By Kristin Jensen • Jan. 15, 2020 -
Amag CEO to step down as troubled pharma looks to sell 2 drugs
Emerging from an activist investor fight, Amag announced a restructuring plan and 2020 sales estimates that fell short of Wall Street expectations.
By Andrew Dunn • Jan. 09, 2020 -
GSK's plan to take over the HIV drug market hasn't worked out
An FDA rejection and modest sales for two marketed products are challenging GSK's argument that two-drug treatments are a better way to treat HIV.
By Jacob Bell • Jan. 06, 2020 -
Pfizer, AbbVie and Gilead among drugmakers boosting prices to start 2020
List prices rose on some of the top-selling medicines in the U.S., including Humira, Opdivo, Prevnar 13 and Biktarvy.
By Andrew Dunn • Jan. 02, 2020 -
Ultragenyx sells European royalty stake in rare disease drug for $320M
Royalty Pharma will add another stake to its expansive collection, while the California biotech gets an immediate injection of cash.
By Andrew Dunn • Dec. 18, 2019 -
SponsoredData alone can't make health improvements happen
Big tech could soon be playing the role of big brother in monitoring our health-related behaviors, with or without consumers' explicit buy-in.
By Pratap Khedkar • Dec. 03, 2019 -
Before 2019 closes, the FDA has 3 key approval decisions to make
The agency has been on an approval tear lately, and more may come as reviews for drugs from Amarin, Allergan and Intra-Cellular wrap up.
By Jacob Bell • Nov. 27, 2019 -
FDA's rapid review pace nets an early approval for Alnylam's second drug
Givosiran, which will be sold as Givlaari, is the second RNAi therapeutic cleared by the agency after Alnylam's Onpattro.
By Jonathan Gardner • Nov. 20, 2019 -
France clears way for wide use of Vertex's Orkambi
By agreeing to reimburse the drug beyond compassionate use, France opens up access to one of the largest cystic fibrosis populations outside the U.S.
By Jonathan Gardner • Nov. 20, 2019 -
Nascent digital therapeutics group lays out best practices, ethics
The two-year-old group is looking to differentiate higher-risk products that claim to treat disease from more general digital health and wellness apps.
By Susan Kelly • Nov. 13, 2019 -
Sage's new drug starts slow, as Wall Street waits for depression data
Few expected Sage's postpartum depression drug Zulresso to start fast. Sales of $1.5 million in its first full quarter on market confirmed those expectations.
By Ned Pagliarulo • Nov. 13, 2019 -
Walgreens reportedly mulling massive private equity buyout
The drugstore retailer is exploring a possible go-private deal, which would be the largest leveraged buyout in history, according to multiple media reports.
By Ben Unglesbee • Nov. 06, 2019
